@article{3080235,
    title = "Dermatitis during radiation for vulvar carcinoma: prevention and
treatment with granulocyte-macrophage colony-stimulating factor
impregnated gauze",
    author = "Kouvaris, JR and Kouloulias, VE and Plataniotis, GA and Balafouta, EJ and and Vlahos, LJ",
    journal = "Wound Repair and Regeneration",
    year = "2001",
    volume = "9",
    number = "3",
    pages = "187-193",
    publisher = "BLACKWELL SCIENCE PUBL INC CAMBRIDGE",
    issn = "1067-1927, 1524-475X",
    doi = "10.1046/j.1524-475x.2001.00187.x",
    abstract = "The aim of this study was to determine the effectiveness of
granulocyte-macrophage colony-stimulating factor (GMCSF) impregnated
gauze in preventing or healing radiation-induced dermatitis, Sixty-one
patients were irradiated for vulvar carcinoma, Thirty-seven applied
steroid cream at irradiated areas throughout radiotherapy (Group A) and
24 patients applied additionally GM-CSF impregnated gauze (40 mug/cm(2)
of skin-irradiated area, twice per day) in addition to the steroid
cream, after 20Gy of irradiation (Group B). The score of skin reactions
(P=0.008, chi(2) test) and the time interval of radiotherapy
interruption (P=0.037, Mann-Whitney U test) were statistically
significantly reduced in Group B patients, Multivariate analysis of
variance showed for this group not only a significant reduction in the
Sum of Gross Dermatitis Scoring (P<0.001, adjusted for Duration of
Dermatitis) but also a significant reduction of the healing time
(P=0.02, adjusted for Sum of Gross Dermatitis Scoring). The pain grading
was less (P=0.014, chi(2) test) and pain reduction was noticed sooner
after the application of GM-CSF impregnated gauze (P=0.0017,
Mann-Whitney U test). Multivariate logistic regression analysis showed
that the only significant effect on dermatitis score is due to Body Mass
Index (P=0.034) and the application of GM-CSF (P=0.008), GM-CSF
impregnated gauze can be effective in preventing and healing
radiation-induced dermatitis and in reducing the interruption intervals
of radiotherapy for vulvar carcinomas."
}